September 16, 2020
Edmund Pezalla, MD, MPH, CEO, Enlightenment Bioconsult LLC, discusses treatment options for multiple sclerosis, highlights results from the ASCLEPIOS I and II studies, and notes why this data can be useful for payers.
Reference: Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. doi:10.1056/NEJMoa1917246